NCT02281058View on ClinicalTrials.gov

Open-label Pilot Study of Abatacept for the Treatment of Vitiligo

PHASE1UnknownINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

May 31, 2018

Conditions

Vitiligo

Interventions

DRUG

Abatacept

self-injected subcutaneous biologic medication

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Brigham and Women's Hospital

OTHER

NCT02281058 - Open-label Pilot Study of Abatacept for the Treatment of Vitiligo | Biotech Hunter | Biotech Hunter